You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,258,098


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,258,098
Title:Antitumoral treatments
Abstract: The present invention relates to combinations of aplidine or aplidine analogues with other titumoral agents, and the use of these combinations in the treatment of cancer, in particular in the treatment of lung cancer, breast cancer, colon cancer, prostate cancer, renal cancer, melanoma, multiple myeloma, leukemia and lymphoma.
Inventor(s): Faircloth; Glynn Thomas (Cambridge, MA), Aviles Marin; Pablo Manuel (Madrid, ES), LePage; Doreen (Cambridge, MA), Izquierdo; Jesus San Miguel (Salamanca, ES), Pandiella; Atanasio (Salamanca, ES)
Assignee: Pharma Mar, S.A. (Madrid, ES)
Application Number:12/278,559
Patent Claims:1. A method of treating a cancer selected from breast cancer, prostate cancer, colon cancer, lung cancer, multiple myeloma, and melanoma, comprising administering to a patient in need of such treatment a therapeutically effective amount of aplidine and a therapeutically effective amount of another drug, wherein said drug is selected from paclitaxel, cisplatin, arsenic trioxide, 5-fluorouracil, carboplatin, 7-ethyl-10-hydroxycamptothecin, etoposide, melphalan, dexamethasone, bortezomib, lenalidomide, idarubicin, and rituximab, and wherein said amounts of both drugs together provide a synergistic effect.

2. A method of increasing the therapeutic efficacy of a drug effective in the treatment of a cancer selected from breast cancer, prostate cancer, colon cancer, lung cancer, multiple myeloma, and melanoma, wherein said drug is selected from paclitaxel, cisplatin, arsenic trioxide, 5-fluorouracil, carboplatin, 7-ethyl-10-hydroxycamptothecin, etoposide, melphalan, dexamethasone, bortezomib, lenalidomide, idarubicin, and rituximab, which comprises administering to a patient with said cancer in need thereof said drug and an amount of aplidine, and wherein the amounts of both drugs together provide a synergistic effect.

3. The method according to claim 1, wherein a therapeutically effective amount of a third drug selected from melphalan, dexamethasone, bortezomib, lenalidomide, and thalidomide is administered.

4. The method according to claim 1, wherein said drug is paclitaxel.

5. The method according to claim 1, wherein said drug is cisplatin.

6. The method according to claim 1, wherein said drug is arsenic trioxide.

7. The method according to claim 1, wherein said drug is 5-fluorouracil.

8. The method according to claim 1, wherein said drug is carboplatin.

9. The method according to claim 1, wherein said drug is 7-ethyl-10-hydroxycamptothecin.

10. The method according to claim 1, wherein said drug is etoposide.

11. The method according to claim 1, wherein said drug is melphalan.

12. The method according to claim 1, wherein said drug is dexamethasone.

13. The method according to claim 1, wherein said drug is bortezomib.

14. The method according to claim 1, wherein said drug is lenalidomide.

15. The method according to claim 1, wherein said drug is idarubicin.

16. The method according to claim 1, wherein said drug is rituximab.

17. The method according to any of claims 4, 5 or 7, wherein said method is a method of treating breast cancer.

18. The method according to any of claims 4, 6, 7 or 8, wherein said method is a method of treating prostate cancer.

19. The method according to any one of claims 5, 6, or 8, wherein said method is a method of treating colon cancer.

20. The method according to any one of claims 6, 7 or 9, wherein said method is a method of treating lung cancer.

21. The method according to any one of claims 10 to 14, wherein said method is a method of treating multiple myeloma.

22. The method according to claim 8, wherein said method is a method of treating melanoma.

23. The method according to claim 3, wherein the second drug is lenalidomidc and the third drug is dexamethasone.

24. The method according to claim 3, wherein the second drug is bortezomib and the third drug is dexamethasone.

25. The method according to claim 3, wherein the second drug is bortezomib and the third drug is lenalidomide.

26. The method according to claim 3, wherein the second drug is dexamethasone and the third drug is thalidomide.

27. The method according to claim 3, wherein the second drug is dexamethasone and the third drug is melphalan.

28. The method according to claim 3, wherein the second drug is melphalan and the third drug is bortezomib.

29. The method according to any one of claims 23 to 28, wherein said method is a method of treating multiple myeloma.

Details for Patent 8,258,098

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2039-03-29
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2039-03-29
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.